Shareholders’ Equity |
9 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||
| Equity [Abstract] | ||||||||||
| Shareholders’ Equity | 7. Shareholders’ Equity
Common Stock
The Company is authorized to issue shares of common stock, par value $ per share. Each share entitles the holder to one vote on matters submitted to stockholders and to receive dividends as and if declared by the Board of Directors.
As of December 31, 2024, the Company had shares of common stock issued and outstanding.
During the year of 2025, the Company completed the following equity issuances in connection with its initial public offering and related activities:
Following these issuances, the Company had shares of its common stock issued and outstanding as of December 31, 2025, including an aggregate of shares of common stock issued during the quarter ended September 30, 2025.
On March 18, 2026, the Company issued an aggregate of shares of Common Stock to Dr. Huijuan Zhong as compensation for services. These shares were issued in reliance on exemption from registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended, as transactions by an issuer do not involve any public offering and are subject to contractual transfer restrictions until 12 months following the Company’s initial public offering. On July 27 and August 7, 2026, the Company issued and shares of common stock, respectively to six nonemployee consultants under the 2026 Plan. On August 20, 2026, the Company effected a 1-for-20 Reverse Stock Split of its common stock. Following these issuances and the effectiveness of the Reverse Stock Split, the Company had shares of common stock issued and outstanding as of September 30, 2026. For further information regarding the measurement and recognition of the related stock-based compensation, see Note 8, Stock-Based Compensation.
Subscriptions Received – Shares to be Issued
In 2019, the Company received $ in cash from an existing investor for a subscription to common stock representing 0.1% of the Company’s then-anticipated total issued and outstanding shares upon completion of the IPO. This amount was recorded as “common stock to be issued” within stockholders’ equity and remained outstanding as of December 31,2024.
Following the successful completion of the IPO, the Company issued shares of common stock during the quarter ended September 30, 2025 to settle this subscription in full. As of September 30, 2026, there were remaining shares or amounts recorded as “common stock to be issued.”
Preferred Stock
The Company is authorized to issue shares of preferred stock at $ per share. The Company’s Board of Directors also has the authority to issue additional preferred stock in one or more classes or series. On June 14, 2024, the Company’s Board of Directors approved the issuance of shares of Series A Super Voting Preferred Stock (“Series A Preferred Stock”) at the par value of $ per share. These shares grant the holders 40% of the total voting power of the Company’s equity voting stock. Holders of the Series A Preferred Stock do not possess any rights to dividends.
shares of preferred stock were issued during the nine months ended September 30, 2026.
|